site stats

Syrs earnings report

WebSYRS Syros Pharmaceuticals Inc. Stock Price & News - WSJ. DJIA 33485.29 0.01% . S&P 500 4105.02 0.36% . U.S. 10 Yr 0/32 Yield 3.405% . 0.13%. Web4 rows · Aug 9, 2024 · Syros Pharmaceuticals, Inc. is estimated to report earnings on 11/04/2024. The upcoming ...

Syros Pharmaceuticals, Inc. (SYRS) - Yahoo!

WebJul 13, 2024 · Syros Pharmaceuticals, Inc. (SYRS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in... WebMar 15, 2024 · Earnings Webcast. PDF HTML. ... On Track to Report PK and Safety Data from Ongoing Dose Confirmation Study of SY-2101 in Mid-2024 ... (BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter and full-year ended … home ready mortgage loans https://thesocialmediawiz.com

SYRS Stock Price Forecast. Should You Buy SYRS? - StockInvest.us

WebMar 31, 2024 · Current Quarter Estimates for SYRS. In the past 30 days, one estimate has gone higher for Syros Pharmaceuticals while no estimates have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from a loss of 70 cents a share 30 days ago, to a loss of 61 cents today, a move of 13%. Web26 rows · Apr 8, 2024 · Syros Pharmaceuticals last posted its quarterly earnings results on March 2nd, 2024. The ... WebMar 1, 2024 · SYRS. is set to give its latest quarterly earnings report on Thursday, 2024-03-02. Here's what investors need to know before the announcement. Analysts estimate that Syros Pharmaceuticals will ... home ready max income limit

Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Tops ... - Nasdaq

Category:Syros Pharmaceuticals (SYRS) Earnings Date & Reports - TipRanks

Tags:Syrs earnings report

Syrs earnings report

Syros Pharmaceuticals, Inc. (SYRS) Moves to Strong Buy: …

WebMar 15, 2024 · Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.61 per share a year ago. WebAug 9, 2016 · SYRS - Syros Pharmaceuticals, Inc. Stock Price and Quote TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. × publish chart save to portfolio create alert compare perf. Candle - advanced Intraday Daily Weekly Monthly Draw Fullscreen Settings SYRS - Stock Price Chart SYRS [NASD]

Syrs earnings report

Did you know?

WebAug 6, 2024 · Syros Pharmaceuticals, Inc.Which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.19 million for the quarter ended June 2024, surpassing the Zacks Consensus... WebApr 10, 2024 · Syros Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros …

WebBased on 5 Wall Street analysts offering 12 month price targets for Syros Pharmaceuticals in the last 3 months. The average price target is $24.00 with a high forecast of $60.00 and a low forecast of $13.00. The average price target represents a 858.08% change from the last price of $2.51. Highest Price Target $60.00. Average Price Target $24.00. WebNov 14, 2024 · Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $2.41 per share versus the Zacks Consensus Estimate of a loss of $3.91. This compares to loss …

WebSyros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the... SYRS : 2.51 (-2.15%) VRDN : 25.41 (+1.97%) WebNov 14, 2024 · Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $2.41 per share versus the Zacks Consensus Estimate of a loss of $3.91. This compares to loss of $4.10 per share a year ago....

WebEarnings Summary For their last quarter, Syros Pharmaceuticals (SYRS) reported earnings of -$1.28 per share, missing the Zacks Consensus Estimate of -$1.27 per share. This …

WebSYRS Stock Price - Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and … homeready movement mortgageWebJan 30, 2024 · NASDAQ: SYRS Syros Pharmaceuticals Stock Earnings Report Current P/E ratio: -0.326 Price (Jan 30, 2024, EOD): $4.85 (Find current average P/E ratios for all … home ready non borrower incomeWebApr 14, 2024 · The Syros Pharmaceuticals stock price fell by -2.15% on the last day (Thursday, 6th Apr 2024) from $2.56 to $2.51. During the last trading day the stock fluctuated 6.61% from a day low at $2.42 to a day high of $2.58. The price has fallen in 7 of the last 10 days and is down by -10.85% for this period. home ready online courseWebSyros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2024. hinton deep learningWebApr 12, 2024 · Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) posted its quarterly earnings data on Thursday, March, 2nd. The company reported ($1.28) EPS for the quarter, missing … homeready need to be first time homebuyerWebRepresents the company's profit divided by the outstanding shares of its common stock. -0.17. 95.53%. EBITDA. Earnings before interest, taxes, depreciation, and amortization, is a measure of a ... hinton dental stansbury parkWebMar 2, 2024 · Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2024. hinton deep learning video by his student